Sara Ebrahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sara Ebrahimi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Desai
University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Ana Sofia Lopez Rodriguez
University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Anthony M. Hachem
University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Keila C. Ostos-Mendoza
University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Nicolas L. Palaskas
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication - Noah Beinart
Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1057, Houston, TX 77030, USA
1 shared publication
Latest Publications
- 22 May 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 435, 133411
Early aortic valve replacement in asymptomatic severe aortic stenosis: A turning point in management
- 22 May 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 435, 133411
Early aortic valve replacement in asymptomatic severe aortic stenosis: A turning point in management
- 3 April 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-11
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis
Purpose of Review To provide an update on the literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis. Recent Findings The diagnosis of immune checkpoint inhibitor myocarditis has evolved to include more reliance on performing endomyocardial biopsy to clarify the diagnosis in selected cases. Additionally, there is recognition of a spectrum of disease both clinically and on endomyocardial biopsy suggesting that there is a range of severity from mild to fulminant. The treatment of immune checkpoint inhibitor myocarditis is shifting towards increased use of additional immunosuppressive medications as steroid sparing agents. There are increased studies including two randomized controlled trials evaluating abatacept in the treatment of immune checkpoint inhibitor myocarditis. Summary This review summarizes the latest literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis and provides our experience and approach to this rare but potentially fatal condition.
- 3 April 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-11
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis
Purpose of Review To provide an update on the literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis. Recent Findings The diagnosis of immune checkpoint inhibitor myocarditis has evolved to include more reliance on performing endomyocardial biopsy to clarify the diagnosis in selected cases. Additionally, there is recognition of a spectrum of disease both clinically and on endomyocardial biopsy suggesting that there is a range of severity from mild to fulminant. The treatment of immune checkpoint inhibitor myocarditis is shifting towards increased use of additional immunosuppressive medications as steroid sparing agents. There are increased studies including two randomized controlled trials evaluating abatacept in the treatment of immune checkpoint inhibitor myocarditis. Summary This review summarizes the latest literature regarding diagnosis and management of immune checkpoint inhibitor myocarditis and provides our experience and approach to this rare but potentially fatal condition.